Key result
Low-dose aspirin reduces MACE ~24% in CKD stages 3-5 but increases major bleeding.
Why the study?
Despite optimal treatments, mortality remains high among patients with chronic kidney disease, prompting an evaluation of the balance between cardiovascular benefits and bleeding risks with low-dose aspirin in stages 3-5 CKD.
Does low-dose aspirin reduce MACE in patients with CKD stages 3-5?
Meta-Analysis (n=8,617)
Does low-dose aspirin reduce MACE in patients with CKD stages 3-5?
Effect estimate: RR 0.76 (95% CI 0.62-0.94)
Absolute Event Rate: 5.24% vs 6.73%
p-value: p=0.0115
Low-dose aspirin provides significant benefits in preventing MACE and mortality in patients with CKD stages 3-5, but increases the risk of major bleeding.
Balances MACE reduction with bleeding risk in CKD stages 3-5; extends meta-analytic data but requires RCT confirmation before practice change.
Chronic kidney disease (CKD) is a global health concern and an independent risk factor for cardiovascular disease. Despite optimal treatments, mortality remains high among CKD patients. This meta-analysis aimed to assess the balance between the cardiovascular benefits and the bleeding risks associated with the use of low-dose aspirin in patients with CKD stages 3–5. Randomized controlled trials (RCTs) regarding the use of low-dose aspirin for cardiovascular primary prevention for patients with CKD were searched in PubMed, Embase, and the Cochrane Library. The Cochrane Collaboration RoB 2.0 tool was used to assess the risk of bias of RCTs. Major adverse cardiovascular events (MACE), including cardiovascular mortality, nonfatal myocardial infarction, and nonfatal stroke, along with other related outcomes, was calculated using a random-effects model to determine hazard ratios and relative risks (RRs). A subgroup analysis was stratified by estimated glomerular filtration rate (eGFR) levels to assess the differential effects of the treatment on patients with varying degrees of kidney function impairment. Five long-term RCTs were identified through systematic searches. Among them, 2 were at low risk, 2 had bias concerns, and 1 was at high risk. Aspirin significantly reduced the risk of MACE (RR, 0.76; 95% CI, 0.62–0.94), cardiovascular mortality (RR, 0.60; 95% CI, 0.43–0.85) and all-cause mortality (RR, 0.78; 95% CI, 0.63–0.96) in patients with CKD stages 3–5 compared to those not taking aspirin. When eGFR < 45 mL/min per 1.73 m2, the use of aspirin was associated with a significant reduction in the risk of myocardial infarction (RR, 0.47; 95% CI, 0.23–0.96) and cardiovascular mortality (RR, 0.47; 95% CI, 0.24–0.92). However, aspirin increased the risk of major bleeding in patients with CKD stages 3–5 compared to those not taking aspirin (RR, 1.50; 95% CI, 1.12, 2.02). Low-dose aspirin provided significant benefits in preventing MACE, cardiovascular mortality and all-cause mortality in patients with CKD stages 3–5, particularly in preventing myocardial infarction, and cardiovascular mortality in those with an eGFR < 45 mL/min per 1.73 m2. However, the risk of major bleeding tended to increase as the eGFR decreased. For patient populations with a high risk of bleeding, it is necessary to re-evaluate the appropriateness of aspirin use.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2025) conducted a meta-analysis in Chronic Kidney Disease (CKD) stages 3-5 (n=8,617). Low-dose aspirin vs. Placebo or standard medical treatment was evaluated on Major adverse cardiovascular events (MACE) (RR 0.76, 95% CI 0.62-0.94, p=0.0115). Low-dose aspirin significantly reduced the risk of major adverse cardiovascular events (RR 0.76) in patients with CKD stages 3-5, though it increased the risk of major bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: